CLINICAL EFFICACY OF BUTYLPHTHALIDE IN THE TREATMENT OF PATIENTS WITH SUBARACHNOID HEMORRHAGE WITH CEREBRAL VASOSPASM AND ITS EFFECT ON NEUROLOGICAL FUNCTION AND SERUM INDEXES

Hua Chen¹, Siwei Que¹, Jing Yi1, Yong Cai^{2, *}

¹Department of Neurosurgery, The First People’s Hospital of Changde City, 415008, Hunan, China - ²Department of Neurosurgery, The First People's Hospital of Huzhou, Huzhou, 313000, Zhejiang, China

Objective: To investigate the clinical efficacy of butylphthalide in the treatment of patients with subarachnoid hemorrhage with cerebral vasospasm and its effect on neurological function and serum indexes. 

Methods: A total of 102 patients with subarachnoid hemorrhage with cerebral vasospasm who were treated in our hospital from September 2020 to May 2022 were selected and divided into an observation group and a control group according to the random number table method, with 51 cases in each group. The patients in the control group were treated with conventional treatment combined with nimodipine, and the patients in the observation group were treated with butylphthalide on the basis of the control group. The clinical efficacy, middle cerebral artery blood flow velocity, inflammatory indexes, serum indexes and prognosis of the two groups of patients before and after treatment were observed. 

Results: The clinical efficacy of the observation group was significantly better than that of the control group (P<0.05). There was no significant difference in the blood flow velocity of the middle cerebral artery between the two groups before treatment (P>0.05); 3 days and 7 days after treatment, the blood flow velocity of the middle cerebral artery in the two groups was significantly lower than before treatment (P<0.05). The groups were significantly lower than the control group (P<0.05). After treatment, the levels of interleukin-6 (IL-6) and C-reactive protein (CRP) in the two groups were significantly lower than those before treatment (P<0.05), and the observation group was significantly lower than the control group (P<0.05). After treatment, the levels of cortisol, central nervous system-specific protein (S100β protein) and neuron-specific enolase (NSE) in the observation group were significantly lower than those before treatment and those in the control group (P<0.05). After treatment, the MRS score of the observation group was significantly lower than that of the control group (P<0.05). 

Conclusion: The use of butylphthalide in the treatment of patients with subarachnoid hemorrhage with cerebral vasospasm has a good clinical effect, which is conducive to improving the level of serum inflammatory factors, reducing the inflammatory response of brain tissue, relieving brain tissue damage, and protecting neurological function. The therapeutic effect is safe and effective.